The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu
Trial record 1 of 1 for:    06073431
Previous Study | Return to List | Next Study

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study (LOTUS-CC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06073431
Recruitment Status : Recruiting
First Posted : October 10, 2023
Last Update Posted : April 25, 2024
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Richard Dunne, University of Rochester NCORP Research Base

Brief Summary:
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.

Condition or disease
Cancer Cachexia (CC)

Detailed Description:


I. To identify multiple distinct diagnostic subtypes within the syndrome of CC as defined by host characteristics (e.g. cachexia symptoms, physical activity, physical function, blood biomarkers including hemoglobin and albumin, and body composition) at baseline and change in these factors over time in patients with cancer at high risk for CC.


I. To determine the association of each CC phenotype with overall survival. II. To validate CC diagnostic phenotypes developed in a separate, independent cachexia observational study performed by our collaborators at Kaiser Permanente.

III. To collect human samples of blood, tumor tissue, and medical images and build a large, comprehensive CC database clinically annotated with cancer-related outcomes, cachexia symptoms, and physical function data.


I. To evaluate for tumor-derived factors contributing to CC by determining the association between interleukin-6 (IL-6) expression in tumors and IL-6 and CC chemokine ligand 2 (CCL2) levels in the blood in patients with CC.

OUTLINE: This is an observational study.

Patients complete surveys over 30 minutes, undergo physical function tests over 30 minutes, undergo collection of blood and archived tumor samples, and wear actigraphy over 24 hours for 7 days to record daily sleep and exercise activity at baseline and 3-month follow-up. Patients' medical records are also reviewed at baseline, 3-month and 1-year follow-up.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
Actual Study Start Date : December 4, 2023
Estimated Primary Completion Date : January 1, 2028
Estimated Study Completion Date : January 1, 2028

Primary Outcome Measures :
  1. Identification of multiple distinct diagnostic subtypes within the syndrome of cancer cachexia (CC) [ Time Frame: Baseline through study completion, assessed up to 1 year follow up ]
    Defined by host characteristics (e.g. cachexia symptoms, physical activity, physical function, blood biomarkers including hemoglobin and albumin, and body composition) at baseline and change in these factors over time in patients with cancer at high risk for CC. First, will examine the distributions of each variable and assess the need for using transformations to achieve normality for continuous variables (log transformation, quartiles, or clinically important thresholds), collapsing similar variables into single categories, and excluding g conditions that are too rare (< 1% of the cohort). Next, will assess statistical correlations using the Jaccard similarity metric for binary variables and the Pearson correlation for continuous variables to determine highly correlated variables that may provide redundant information.

Biospecimen Retention:   Samples With DNA
Blood and tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing treatment for non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, colorectal cancer.

Inclusion Criteria:

  • • Have a primary diagnosis of unresectable or stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer

    • Note: Patients do not need to have cachexia to be eligible

      • Plan to start first-line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, interventional clinical trial) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks.

    • NOTE: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant treatment and have since recurred are still eligible if such treatment ended > 6 months prior to enrollment. Patients receiving concurrent radiation with systemic therapy or receive local therapy alone (surgery, radiation therapy [RT]) prior to first line therapy remain eligible. Patients receiving maintenance treatment after first line therapy are not eligible

      • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
      • Be able to understand, speak and read English
      • Be 18 years of age or older

Exclusion Criteria:

  • • Have contraindications to physical function assessments (30-second arm curl, Timed-Up-And-Go test, or 30-second chair-stand test) per the treating provider or their designee

    • Have any planned major surgeries within the next 3 months
    • Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than early local staged non-melanoma skin cancer
    • Be pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT06073431

Layout table for location contacts
Contact: Ashley Mack, MS 585-275-1090

Layout table for location information
United States, Illinois
Carle Cancer Center NCORP (CARLE) Active, not recruiting
Urbana, Illinois, United States, 61801
United States, Michigan
Cancer Research Consortium of West Michigan (CRCWM) Active, not recruiting
Grand Rapids, Michigan, United States, 49503
United States, Ohio
Columbus NCORP (COLUMBUS) Active, not recruiting
Columbus, Ohio, United States, 43215
United States, Wisconsin
Cancer Research of Wisconsin and Northern Michigan Consortium (CROWN) Active, not recruiting
Green Bay, Wisconsin, United States, 54301
Aurora NCORP (AURORA) Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Neha Glandt    414-219-4718   
Sponsors and Collaborators
University of Rochester NCORP Research Base
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Richard Dunne, MD, MS University of Rochester NCORP Research Base
Layout table for additonal information
Responsible Party: Richard Dunne, Principal Investigator, University of Rochester NCORP Research Base Identifier: NCT06073431    
Other Study ID Numbers: URCC-22063
OT2CA278664 ( U.S. NIH Grant/Contract )
First Posted: October 10, 2023    Key Record Dates
Last Update Posted: April 25, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Currently, there is no plan to make individual participant data (IPD) available to other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Wasting Syndrome
Weight Loss
Body Weight Changes
Body Weight
Metabolic Diseases
Nutrition Disorders